Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-101 plus nivolumab in advanced melanoma
2018-001346-34Phase 2Unknown
- Sponsor
- Immodulon Therapeutics
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of IMM-101 and nivolumab in melanoma (2 cohorts), sponsored by Immodulon Therapeutics. Primary endpoint: Overall response rate. Status: unknown.
02
Drugs
IMM-101nivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-001346-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001346-34.